NEW YORK (GenomeWeb News) – Gene Bridges said today that the Chugai Pharmaceutical has expanded a license for the company's recombination technology.

The Japanese pharmaceutical firm agreed to expand a commercial license for the Red/ET technology that the companies originally struck in 2005.

Patented in Japan as a "Novel DNA Cloning Method," the Red/ET technology is used for generating targeting vectors or modifying E. coli chromosomes. The methodology allows cloning, subcloning, and DNA modification at any position, Gene Bridges said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.